ID: ALA3337768

Max Phase: Preclinical

Molecular Formula: C19H29N5O5

Molecular Weight: 407.47

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCC(CCC)C(=O)O[C@H]1[C@H](n2cnc3c(N)ncnc32)O[C@H](CO)[C@@]1(C)O

Standard InChI:  InChI=1S/C19H29N5O5/c1-4-6-11(7-5-2)18(26)29-14-17(28-12(8-25)19(14,3)27)24-10-23-13-15(20)21-9-22-16(13)24/h9-12,14,17,25,27H,4-8H2,1-3H3,(H2,20,21,22)/t12-,14+,17-,19-/m1/s1

Standard InChI Key:  UIZZGMMPIOLAQU-MEQBGZRUSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 407.47

Molecular Weight (Monoisotopic): 407.2169

AlogP: 1.18

#Rotatable Bonds: 8

Polar Surface Area: 145.61

Molecular Species: NEUTRAL

HBA: 10

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 10

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.86

CX Basic pKa: 3.94

CX LogP: 1.65

CX LogD: 1.65

Aromatic Rings: 2

Heavy Atoms: 29

QED Weighted: 0.55

Np Likeness Score: 1.03

References

1. Petrelli R, Meli M, Vita P, Torquati I, Ferro A, Vodnala M, D'Alessandro N, Tolomeo M, Del Bello F, Kusumanchi P, Franchetti P, Grifantini M, Jayaram HN, Hofer A, Cappellacci L..  (2014)  From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3'-C-methyladenosine.,  24  (22): [PMID:25304896] [10.1016/j.bmcl.2014.09.046]

Source

Source(1):

• Scientific Literature